Table 3 Association of pathologic features of aggressiveness with body mass index (BMI)⩾35 (vs BMI <25) after multivariable adjustment for patient age and pre-operative PSA
Pathologic feature | Mayo Rochester (N=1631) | |
|---|---|---|
OR (95% CI) | P-value | |
Prostatic volume (cm 3 ; doubling) | 1.76 (1.46–2.13) | <0.0001 |
Tumor volume (cm 3 ; doubling) | 1.09 (1.04–1.14) | 0.0007 |
Pathologic T stage a | ||
pT2 | REF | — |
pT3, pT4, pTxN+ | 1.15 (0.81–1.63) | 0.45 |
Pathologic Gleason score | ||
⩽6 | REF | — |
7 | 1.86 (1.44–2.39) | <0.001 |
8–10 | 2.32 (1.54–3.48) | <0.001 |
Positive margin | ||
No | REF | — |
Yes | 1.68 (1.15–2.47) | 0.008 |
Seminal vesicle involvement | ||
No | REF | — |
Yes | 1.24 (0.76–2.02) | 0.38 |
Extra-capsular extension | ||
No | REF | — |
Yes | 1.28 (0.91–1.81) | 0.16 |
